Triple Recycling Processes Impact Systemic and Local Bioavailability of Orally Administered Flavonoids

AAPS Journal

Volumn 17, Issue 3, 2015, Pages 723-736

  Dai, Peimin ^a,b   Zhu, Lijun ^a   Luo, Feifei ^a   Lu, Linlin ^a   Li, Qiang ^a,b   Wang, Liping ^a,d   Wang, Ying ^a,b   Wang, Xinchun ^d   Hu, Ming ^a,c   Liu, Zhongqiu ^a,b  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF HOUSTON   (United States)

^d SHIHEZI UNIVERSITY   (China)

Author keywords

enteric recycling; enterohepatic recycling; flavonoid; local recycling; phase II metabolism

Indexed keywords

ACACETIN; BETA GLUCURONIDASE; BETA-GLUCONO-1,5-LACTONE; FLAVONE DERIVATIVE; FLAVONOID; GLUCONIC ACID; GLUCURONIDE; GLYCOSIDE; GLYCOSYLCERAMIDASE; LACTONE; SACCHARIC ACID; SACCHAROLACTONE; TILIANIN;

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BILE; BIOAVAILABILITY; HALF LIFE TIME; INTESTINE; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; RAT; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BILE; BIOLOGICAL AVAILABILITY; FLAVONES; FLAVONOIDS; GLUCARIC ACID; GLUCONATES; GLUCURONIDASE; GLUCURONIDES; GLYCOSIDES; HALF-LIFE; INTESTINES; LACTASE-PHLORIZIN HYDROLASE; LACTONES; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84940003747     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-015-9732-x     Document Type: Article

References (42)

1. Hu M. Commentary: bioavailability of flavonoids and polyphenols: call to arms. Mol Pharm. 2007;4(6):803–6.
2. Xia B, Zhou Q, Zheng Z, Ye L, Hu M, Liu Z. A novel local recycling mechanism that enhances enteric bioavailability of flavonoids and prolongs their residence time in the gut. Mol Pharm. 2012;9(11):3246–58.
3. Jia X, Chen J, Lin H, Hu M. Disposition of flavonoids via enteric recycling: enzyme-transporter coupling affects metabolism of biochanin A and formononetin and excretion of their phase II conjugates. J Pharmacol Exp Ther. 2004;310(3):1103–13.
4. Jeong EJ, Jia X, Hu M. Disposition of formononetin via enteric recycling: metabolism and excretion in mouse intestinal perfusion and Caco-2 cell models. Mol Pharm. 2005;2(4):319–28.
5. Manwaring WH. Enterohepatic circulation of estrogens. Calif W Med. 1943;59(5):257.
6. Liu Y, Liu Y, Dai Y, Xun L, Hu M. Enteric disposition and recycling of flavonoids and ginkgo flavonoids. J Alternat Complement Med (New York, NY). 2003;9(5):631–40.
7. Chen J, Lin H, Hu M. Metabolism of flavonoids via enteric recycling: role of intestinal disposition. J Pharmacol Exp Ther. 2003;304(3):1228–35.
8. Fresco P, Borges F, Diniz C, Marques MP. New insights on the anticancer properties of dietary polyphenols. Med Res Rev. 2006;26(6):747–66.
9. Liu Z, Hu M. Natural polyphenol disposition via coupled metabolic pathways. Expert Opin Drug Metab Toxicol. 2007;3(3):389–406.
10. Liu X, Tam VH, Hu M. Disposition of flavonoids via enteric recycling: determination of the UDP-glucuronosyltransferase isoforms responsible for the metabolism of flavonoids in intact Caco-2 TC7 cells using siRNA. Mol Pharm. 2007;4(6):873–82.
11. Wei Y, Wu B, Jiang W, Yin T, Jia X, Basu S, et al. Revolving door action of breast cancer resistance protein (BCRP) facilitates or controls the efflux of flavone glucuronides from UGT1A9-overexpressing HeLa cells. Mol Pharm. 2013;10(5):1736–50.
12. Liu Y, Hu M. Absorption and metabolism of flavonoids in the caco-2 cell culture model and a perused rat intestinal model. Drug Metab Dispos: Biol Fate Chem. 2002;30(4):370–7.
13. Chen J, Wang S, Jia X, Bajimaya S, Lin H, Tam VH, et al. Disposition of flavonoids via recycling: comparison of intestinal versus hepatic disposition. Drug Metab Dispos: Biol Fate Chem. 2005;33(12):1777–84.
14. Wang SW, Kulkarni KH, Tang L, Wang JR, Yin T, Daidoji T, et al. Disposition of flavonoids via enteric recycling: UDP-glucuronosyltransferase (UGT) 1As deficiency in Gunn rats is compensated by increases in UGT2Bs activities. J Pharmacol Exp Ther. 2009;329(3):1023–31.
15. Yasuda T, Mizunuma S, Kano Y, Saito K, Oshawa K. Urinary and biliary metabolites of genistein in rats. Biol Pharm Bull. 1996;19(3):413–7.
16. Jiang J, Yuan X, Wang T, Chen H, Zhao H, Yan X, et al. Antioxidative and Cardioprotective Effects of Total Flavonoids Extracted from Dracocephalum moldavica L. Against Acute Ischemia/Reperfusion-Induced Myocardial Injury in Isolated Rat Heart. Cardiovasc Toxicol. 2014.
17. Nam KW, Kim J, Hong JJ, Choi JH, Mar W, Cho MH, et al. Inhibition of cytokine-induced IkappaB kinase activation as a mechanism contributing to the anti-atherogenic activity of tilianin in hyperlipidemic mice. Atherosclerosis. 2005;180(1):27–35.
18. Hernandez-Abreu O, Castillo-Espana P, Leon-Rivera I, Ibarra-Barajas M, Villalobos-Molina R, Gonzalez-Christen J, et al. Antihypertensive and vasorelaxant effects of tilianin isolated from Agastache mexicana are mediated by NO/cGMP pathway and potassium channel opening. Biochem Pharmacol. 2009;78(1):54–61.
19. Ahn MR, Kunimasa K, Kumazawa S, Nakayama T, Kaji K, Uto Y, et al. Correlation between antiangiogenic activity and antioxidant activity of various components from propolis. Mol Nutr Food Res. 2009;53(5):643–51.
20. Jiang L, Fang G, Zhang Y, Cao G, Wang S. Analysis of flavonoids in propolis and Ginkgo biloba by micellar electrokinetic capillary chromatography. J Agric Food Chem. 2008;56(24):11571–7.
21. Bhat TA, Nambiar D, Tailor D, Pal A, Agarwal R, Singh RP. Acacetin inhibits in vitro and in vivo angiogenesis and downregulates stat signaling and VEGF expression. Cancer Prev Res (Philadelphia, Pa). 2013;6(10):1128–39.
22. Watanabe K, Kanno S, Tomizawa A, Yomogida S, Ishikawa M. Acacetin induces apoptosis in human T cell leukemia Jurkat cells via activation of a caspase cascade. Oncol Rep. 2012;27(1):204–9.
23. Wang SW, Chen J, Jia X, Tam VH, Hu M. Disposition of flavonoids via enteric recycling: structural effects and lack of correlations between in vitro and in situ metabolic properties. Drug Metab Dispos: Biol Fate Chem. 2006;34(11):1837–48.
24. Hu M, Chen J, Lin H. Metabolism of flavonoids via enteric recycling: mechanistic studies of disposition of apigenin in the Caco-2 cell culture model. J Pharmacol Exp Ther. 2003;307(1):314–21.
25. Sesink AL, Arts IC, Faassen-Peters M, Hollman PC. Intestinal uptake of quercetin-3-glucoside in rats involves hydrolysis by lactase phlorizin hydrolase. J Nutr. 2003;133(3):773–6.
26. Day AJ, Gee JM, DuPont MS, Johnson IT, Williamson G. Absorption of quercetin-3-glucoside and quercetin-4'-glucoside in the rat small intestine: the role of lactase phlorizin hydrolase and the sodium-dependent glucose transporter. Biochem Pharmacol. 2003;65(7):1199–206.
27. Day AJ, Canada FJ, Diaz JC, Kroon PA, McLauchlan R, Faulds CB, et al. Dietary flavonoid and isoflavone glycosides are hydrolysed by the lactase site of lactase phlorizin hydrolase. FEBS Lett. 2000;468(2–3):166–70.
28. Wilkinson AP, Gee JM, Dupont MS, Needs PW, Mellon FA, Williamson G, et al. Hydrolysis by lactase phlorizin hydrolase is the first step in the uptake of daidzein glucosides by rat small intestine in vitro. Xenobiotica Fate Foreign Compd in Biol Syst. 2003;33(3):255–64.
29. Chen Y, Wang J, Jia X, Tan X, Hu M. Role of intestinal hydrolase in the absorption of prenylated flavonoids present in Yinyanghuo. Molecules (Basel, Switzerland). 2011;16(2):1336–48.
30. Mackey AD, McMahon RJ, Townsend JH, Gregory 3rd JF. Uptake, hydrolysis, and metabolism of pyridoxine-5'-beta-d-glucoside in Caco-2 cells. J Nutr. 2004;134(4):842–6.
31. Mizuma T, Fuseda N, Hayashi M. Kinetic characterization of glycosidase activity from disaccharide conjugate to monosaccharide conjugate in Caco-2 cells. J Pharm Pharmacol. 2005;57(5):661–4.
32. Kineman BD, Brummer EC, Paiva NL, Birt DF. Resveratrol from transgenic alfalfa for prevention of aberrant crypt foci in mice. Nutr Cancer. 2010;62(3):351–61.
33. Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos: Biol fate Chem. 2004;32(3):314–20.
34. Couture P, Lamarche B. Ezetimibe and bile acid sequestrants: impact on lipoprotein metabolism and beyond. Curr Opin Lipidol. 2013;24(3):227–32.
35. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467–94.
36. Jeong EJ, Liu Y, Lin H, Hu M. Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos: Biol fate Chem. 2005;33(6):785–94.
37. Sun D, Jones NR, Manni A, Lazarus P. Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo. Cancer Prev Res (Philadelphia, Pa). 2013;6(7):719–30.
38. Trdan Lusin T, Trontelj J, Mrhar A. Raloxifene glucuronidation in human intestine, kidney, and liver microsomes and in human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos: Biol Fate Chem. 2011;39(12):2347–54.
39. Chen J, Lin H, Hu M. Absorption and metabolism of genistein and its five isoflavone analogs in the human intestinal Caco-2 model. Cancer Chemother Pharmacol. 2005;55(2):159–69.
40. Xu H, Kulkarni KH, Singh R, Yang Z, Wang SW, Tam VH, et al. Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Mol Pharm. 2009;6(6):1703–15.
41. Rong Z, Xu Y, Zhang C, Xiang D, Li X, Liu D. Evaluation of intestinal absorption of amtolmetin guacyl in rats: breast cancer resistant protein as a primary barrier of oral bioavailability. Life Sci. 2013;92(3):245–51.
42. Jiang W, Xu B, Wu B, Yu R, Hu M. UDP-glucuronosyltransferase (UGT) 1A9-overexpressing HeLa cells is an appropriate tool to delineate the kinetic interplay between breast cancer resistance protein (BRCP) and UGT and to rapidly identify the glucuronide substrates of BCRP. Drug Metab Dispos: Biol Fate Chem. 2012;40(2):336–45.